TY - JOUR T1 - Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity JF - Evidence Based Medicine JO - Evid Based Med SP - 12 LP - 12 DO - 10.1136/eb-2013-101384 VL - 19 IS - 1 AU - Yair Lotan Y1 - 2014/02/01 UR - http://ebm.bmj.com/content/19/1/12.abstract N2 - Commentary on: Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535–43.OpenUrlCrossRefPubMedWeb of Science The management of urolithiasis represents a common and costly problem for healthcare services. Up to 15% of the general population may be affected at some point in their lives and 25–50% of cases will recur.1 ,2 While minimally invasive surgical treatments can treat most of the upper tract calculi, acute stone events and surgical treatment persist as a significant source of morbidity for patients with recurrent urolithiasis. Consequently, the prevention of stone recurrence is an appealing strategy. Although the benefit of dietary modification in preventing stone formation has long been recognised,3 drug treatments have been shown to provide additional protection beyond that of dietary measures alone.4 The goal … ER -